Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SAR3419 plus rituximab in relapsed or refractory diffuse large B-cell lymphoma
2011-002865-39Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2012
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of coltuximab ravtansine in diffuse large B-cell lymphoma (DLBCL), sponsored by Sanofi. Primary endpoint: Objective Response Rate. Started Jul 2012; status: completed.
02
Drugs
coltuximab ravtansine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2011-002865-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002865-39.